Latest Manufacturing Operations News

Iperion reported a lower loss for the year ended 31 March 2026, but its cash reserves and net assets fell sharply, leaving the NZX-listed materials company reliant on related-party funding and director support. Its Pathoglaze manufacturing operation is also being moved from Malaysia to Singapore while customer trials continue.

PPK Group has converted the sale of its Craig International Ballistics stake into a substantially stronger balance sheet, reporting a $19.2 million FY2026 profit and $27.7 million in cash. The challenge now is turning that one-off windfall into a durable operating business without overpaying or losing patience.

EBR Systems’ new Santa Clara manufacturing facility has entered the FDA’s pre-approval inspection process, marking a key regulatory step for its wireless cardiac pacing business. The company continues to expect approval by the end of 2026, but the inspection does not yet amount to clearance.

OncoSil Medical has moved closer to local production after contract manufacturer Cyclotek secured ISO 13485 certification for its quality management system. Production at the Macquarie Park facility remains targeted for the end of 2Q FY27, subject to further regulatory approval.

BluGlass Limited reported a 5% reduction in its net loss to A$10.39 million for FY26 despite a 10% revenue dip, boosted by new US defence and industry contracts and a significant capital raise to fund growth.

6K Additive surged to a US$13.3 million half-year revenue, up 73% year-on-year, driven by strong demand in its Powder and Alloy segments. The company is on track to nearly quadruple production capacity by the end of 2026, supported by substantial US government funding and a new EXIM loan facility.

Bega Cheese Limited has delivered a robust FY2026 with a $54.8 million statutory profit, a 6.7% revenue increase, and a raised final dividend of 7.5 cents per share. The company is advancing its strategic growth plans focused on high-protein products, international expansion, and sustainability initiatives.

Entropy Neurodynamics has partnered with BioCina to establish GMP manufacturing for its intravenous psilocin formulation TRP-8803, a critical step toward late-stage clinical trials and commercialisation.

Reliance Worldwide Corporation has agreed to an exclusivity period with Brookfield Capital Partners over a A$4.75 per share acquisition proposal, valuing the company at around A$4.1 billion. The deal includes a 30-day go-shop provision allowing alternative bids.

EBR Systems marked a commercial milestone with over 100 WiSE CRT implants and secured purchasing agreements with three major US healthcare networks. The company is progressing toward Medicare coverage and scaling manufacturing, supported by a near-complete A$150 million capital raise.

Wide Open Agriculture (ASX: WOA) has taken a significant step towards a capital-light production model by signing a non-binding framework agreement with Proeon Foods for contract manufacturing of its lupin-based ingredients, including exclusive Indian distribution rights.

James Hardie Industries posted a 64% jump in Q1 FY27 net sales to $1.475 billion, powered by the AZEK acquisition and solid organic growth. The company exceeded EBITDA guidance and raised its full-year outlook, targeting robust sales and cash flow growth amid cautious housing market assumptions.